natgillin/translations-raw huggingface dataset:
A method of making an engine coolant additive according to any of claims 1 to 12, the method comprising: 
Postupak za dobivanje aditiva za rashladno sredstvo motora prema bilo kojem od zahtjeva 1 do 10, naznačen time da postupak sadrži:
The suspension of fixed cells were applied to glass microscope slides and air-dried. 
Suspenzija fiksiranih stanica je nanošena na staklene mikroskopske pločice i sušena na zraku.
The recombinant AAV vector for use according to any one of claims 1-5, wherein the method comprises administering the vector by direct injection into: (i) a ventricle of the brain; (ii) a lateral ventricle of the brain; or (iii) the fourth ventricle of the brain. 
Rekombinantni AAV vektor za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačen time da postupak sadrži davanje vektora izravnim ubrizgavanjem u: (1) ventrikulu mozga; (1i) lateralnu ventrikulu mozga; ili (iii) četvrtu ventrikulu mozga.
Preferably, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1. 
PATENTNI ZAHTJEVI Sastav koji obuhvaća održivu bakteriju koja je deponirana pod pristupnim brojem NCIMB 42380 ili održivu bakteriju koja ima 16s rRNK sekvencu koja je najmanje 98% identična sa SEQ ID NO:1, za upotrebu u postupku liječenja ili prevencije raka.
The process according to Claim 12, wherein the composition is added after the final carbonatation saturator. 
Postupak prema zahtjevu 12, naznačen time da se pripravak dodaje nakon konačnog karbonatacijskog saturatora.
The pharmaceutical composition for use according to embodiments 1-9 or 27 wherein (i) m is a positive integer and R12, R22 and R42, in combination comprise at least two allyl or vinyl moieties or (ii) n is a positive integer and R12, R32 and R42, in combination, comprise at least two allyl or vinyl moieties. 
Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje (1) m je pozitivan cijeli broj 1 R12, R2 1 Ra, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka ili (1) n je pozitivan cijeli broj 1 R2, R32 1 Ra, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka.
The most preferred compounds are compound No. 1, compound No. 21, compound No. 4, compound No. 5, compound No. 36, compound No. 69, compound No. 110, compound No. 111, compound No. 112, compound No. 229 and compound No. 37. 
Spoj prema zahtjevu 1, 2 ili 3 naznačen time da spoj je odabran od Spoja br. 1, Spoja br.21, Spoja br. 4, Spoja br. 5, Spoja br. 36, No. 69, Spoja br. 110, Spoja br. 111, Spoja br, 112, Spoja br. 2291 Spoja br. 37
Use of a composition comprising a cobalt-bearing alkyd polymer as a polymerization agent in coatings, said polymer comprising cobalt carboxylate sequences, and having a cobalt content of 0.5 to 6% by weight, and a mean molecular weight of more than 3000. 
Spoj za upotrebu kao sredstvo za polimerizaciju u premazima, koji sadrži alkidni polimer s kobaltom sa sadržajem kobalta od 0,5 do 6 % po masi, s prosječnom molekulskom masom većom od 3000 i s karboksilatnim sekvencama kobalta, čija je značajka to što navedeni polimer ima kiselost manju od 40 mg KOH/g, a poželjno manju od 20 mg KOH/g.
A compound of formula (I) and their pharmaceutically acceptable salt, solvate or polymorph thereof wherein 
Spoj s formulom (I) [image] i njegova farmaceutski prihvatljiva sol, solvat ili njihov polimorf naznačen time da
14 it is shown that an opening 37 is already left open in the layers 32 and 34 so that after placement of the wall element 2 only layer 33 should be processed in order to finish the wall opening 37 to be able to mount the window. 
14 prikazano je da je otvor 37 unaprijed otvoren u slojevima 32 i 34 tako se nakon postavljanja zidnog elementa 2 treba obraditi samo sloj 33 kako bi se dovršio otvor u zidu 37 kako bi se mogao postaviti prozor.
The method of claim 1, wherein said aqueous solution in step (c) is Water For Injection (WFI). 
Postupak sukladan zahtjevima od I do 6, naznačen time, da je spomenuta vodena otopina u koraku (b) voda za injektiranje (WFI).
A conjugate comprising an antibody of any one of claims 1 to 15 coupled to a therapeutic agent. The conjugate of claim 18 wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji sadrži protutijelo sukladno patentnom zahtjevu 1 spojeno s terapeutskim sredstvom, pri čemu je terapeutsko sredstvo poželjno toksin, radioizotop, lijek ili citotoksično sredstvo.
The method as recited in Clause 19 wherein said additional therapeutic agent is selected from the group consisting of benzodiazepines, and antipsychotics. 
Spoj za uporabu prema zahtjevu 6, naznačen time da se navedeno dodatno terapijsko sredstvo bira iz skupine koju čine benzodiazepini, te antipsihotici.
A herbicide composition comprising as component (A) at least two herbicidally active a-monocarboxyl fatty acids which, independently of one another contain hydrocarbon chains of 8 to 10 carbon atoms and are present in a ratio of between 65:35 to 40:60, wherein the a-monocarboxyl fatty acids are selected from the group consisting of caprylic acid, pelargonic acid, and capric acid; and as component (B) at least one ALS inhibitor selected from the group consisting of iodosulfuron-methyl, foramsulfuron, mesosulfuron-methyl, flazasulfuron and thiencarbazone-methyl, wherein the weight ratio of components (A) and (B) is in the range of from 30,000:1 to 167:1; and 
HR P20181951 T1 PATENTNI ZAHTJEVI Kombinacija herbicida koja sadrži kao komponentu (A) kaprilnu kiselinu i kaprinsku kiselinu u omjeru miješanja od između 65: 35 do 40:60 i kao komponentu (B) barem jedan ALS inhibitor sele odabran iz skupine herbicidno aktivnih sulfonilurea i sulfonamida, pri čemu je sulfonilurea iz komponente (B) odabrana iz skupine koju čine jodosulfuron-metil, foramsulfuron, mezosulfuron-metil, flazasulfuron, amidosulfuron i etoksisulfuron i sulfonamid iz komponente (B) je tienkarbazon-metil.
Viscoelastic gels and hydrogels according to any one of claims 1-7, wherein hyaluronic acid has a total concentration from 10 to 40 mg/ml, preferably from 20 to 30 mg/ml. 
Viskoelastični gelovi 1 hidrogelovi za primjenu prema bilo kojem od patentnih zahtjeva 1-7, naznačeni time da je ukupna koncentracija hialuronske kiseline od 10 do 40 mg/mL, preferirano od 20 do 30 mg/mL.
A process for the preparation of compound (I'-b) according to the following scheme: wherein R is C1-C6 linear, branched or cyclic alkyl chain and preferably ethyl, said process being characterised in that the reaction between (I'-a) and 4-chloroaniline is performed under heating in a solvent which forms an azeotropic mixture with water. 
Å o og la 1'-b gdje R je C;-C4 linearni, razgranati ili ciklički alkilni lanac i poželjno etil, taj postupak je naznačen time što se reakcija između (1-a) i 4-kloranilina provodi uz zagrijavanje u otapalu koje 10
The aqueous pharmaceutical suspension according to claim 1, wherein the particle size is less than 50 um for at least 90% of the fexofenadine zwitterionic dihydrate Form I. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što veličina čestica je manja od otprilike 40 mm za najmanje otprilike 90 % dvojnoionskog dihidratnog Oblika I feksofenadina.
The use of a peptide of general formula (I) according to any of claims 1 to 9 in the preparation of a cosmetic or pharmaceutical composition for treating, cleaning or caring for the skin. 
Uporaeba peptida prema zahtjevu 1, naznačena time, što se koristi za pripremanje kozmetičke ili farmaceutske smjese za tretiranje, čišćenje ili njegu kože.
A building material composition comprising the additive of claim 11, a filler, a mineral binder and/or a water-insoluble polymer-binder. 
Smjesa građevnih materijala, naznačena time što sadrži aditiv u skladu s patentnim zahtjevom 8, punilo, mineralno vezivo i/ili polimerno vezivo netopljivo u vodi.
This usually leads to cleaner fields and higher purity of the harvested commodity as well as to higher yields of the respective crop, in particular brassica napus (oilseed rape, canola). 
Ovo obično dovodi do čistijih polja 1 veće čistoće požnjevenog materijala, kao i većim prinosima odgovarajuće kulture, posebno Brassica napus (uljana repica, kanola).
An aqueous composition according to claims 1 to 9, further comprising a reactive compound selected from the group consisting of formaldehyde, ethanol, chlorophorm, trichloroethylene, acetone, polyethylene glycol tert-octylphenyl ether, deoxycholate, diethylpyrocarbonate, sulphite, Na2S2O5, beta-proprio-lacton, polysorbate optionally Polysorbate 20 or Polysorbate 80, O2, phenol, pluronic type copolymers, and a combination of any thereof. 
Vodeni pripravak sukladno zahtjevima 1 do 9, koja dalje sadrži reaktivni spoj odabran iz skupine sastavljenu od formaldehida, etanola, kloroforma, trihloroetilena, acetona, polietilen glikol terc-oktilfenil etera, deoksikolata, dietilpirokarbonata, sulfita, Na,S205, beta-proprio-laktona, polisorbata, opciono Polisorbata 20 ili Polisorbata 80, O,, fenola, kopolimera pluronskog tipa, i bilo koje njihove kombinacije.
The alkalizing agent can be one of meglumine, calcium carbonate, sodium sulfate, sodium bicarbonate or combinations thereof. 
Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 16, naznačena time što se alkalizirajuće sredstvo sastoji od meglumina, kalcijeva karbonata, natrijeva sulfata, natrijeva bikarbonata ili kombinacija navedenog.
Method according to claim 6, wherein said personal data storage unit comprises data scrambled by said personal scrambling key and wherein said transaction request comprises data access information for identifying the data to be accessed, the method further comprises the step of: descrambling at least part of the data identified in the data access information and stored in said personal data storage unit using the personal scrambling key. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što navedena jedinica za spremanje osobnih podataka sadrži podatke ispremetane navedenim osobnim ključem za premetanje, te što navedeni zahtjev za transakcijom sadrži informacije o pristupu podacima radi identificiranja podataka koje treba procijeniti, gdje postupak dodatno uključuje korak: raspremetanja u najmanju ruku dijela podataka identificiranih u informacijama o pristupu podacima i spremljenih u navedenoj jedinici za spremanje osobnih podataka uz upotrebu osobnog ključa za premetanje.
A glucocorticoid contained in a delayed-release dosage form for use according to any one of the previous claims, wherein the glucocorticoid is cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, budesonide, dexamethasone, fludrocortisone, fluocortolone, cloprednole, deflazacort, triamcinolone, preferably prednisone, and the corresponding salts and esters thereof. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je glukokortikoid kortizon, hidrokortizon, prednizon, prednizolon, metilprednizolon, budezonid, deksametazon, fludrokortizon, fluokortolon, kloprednol, deflazakort, triamkinolon, poželjno prednizon ili prednizolon, i njihove odgovarajuće soli 1 esteri.
A polymer conjugate of an indolocarbazole compound of the general formula (I): wherein Ra and Rb are independently a hydrogen or an organic residue selected from the group consisting of substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, hydroxy, lower alkoxy, carboxy or alcoxycarbonyl; or Ra and Rb together form a 5-7 member cyclic structure fused directly to the indolo[2,3-a]carbazole nucleus structure, containing 0, 1 or 2 heteroatoms and optionally containing a carbonyl group and the cyclic structure being unsubstituted or substituted by at least one substituent group selected from a carbonyl group or W1 or W2 and wherein if a heteroatom member of the cyclic structure is nitrogen, the nitrogen is substituted by the residue R3; and wherein Rc and Rd are 
PATENTNI ZAHTJEVI Formula (I) gdje su R* i R" nezavisno vodik ili organski ostatak izabran iz grupe koju čine supstituirani ili nesupstituirani niži alkil, supstituirani ili nesupstituirani niži alkenil, supstituirani ili nesupstituirani niži alkinil, hidroksi, niži alkoksi, karboksi ili alkoksikarbonil; ili R* i R" zajedno formiraju 5-7 -članu cikličnu strukturu fuzioniranu direktno za strukturu jezgra indolo[2,3-a] karbazola, koja sadrži 0, 1 ili 2 heteroatoma i koja izborno sadrži karbonil grupu i cikličnu strukturu koja je nesupstituirana ili supstituirana sa najmanje jednom supstituirajućom grupom izabranom od karbonil grupe ili W' ili
C3-5cycloalkyl substituted with one group selected from: -CO2CH3, -CONH2, 
C3-5cikloalkil supstituiran s jednom skupinom odabranom od sljedećih:
Water is added to the residue and extracted with ethyl acetate (2x30 mL). 
Ostatku se doda voda, te ekstrahira etil-acetatom (2 x 30 ml).
Manufacturing method, according to claim 14, characterized in that the washing step comprises a second washing phase, after the first washing phase, with the following steps: Bathing the trousers for neutralising the K2Mn04, 
Postupak proizvodnje, u skladu s patentnim zahtjevom 14, naznačen time, da nakon prve faze ispiranja korak pranja sadržava drugu fazu ispiranja, sa slijedećim koracima:
Preparation of Nicotine Solutions 
Priprema otopine nikotina
The method of items 5 to 9, wherein the (±)-A9-tetrahydrocannabinol comprises at least about 95% by weight, preferably at least about 98% by weight and more preferably at least about 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema zahtjevima 1 do 5, naznačen time da (+)-A'-tetrahidrokanabinol sadrži najmanje oko 95% težinski, poželjno najmanje oko 98% težinski i još poželjnije najmanje oko 99% težinski trans-(-)-A*- tetrahidrokanabinola i trans-(+)-A*-tetrahidrokanabinola bazirano na ukupnoj količini kanabinoida.
The reaction is conveniently effected at a temperature in the range, for example, 10 to 150°C (or the boiling point of the solvent), suitably in the range 20 to 90°C. 
Reakcija se prikladno provodi u temperaturnom rasponu od, na primjer, 10 do 150 "C (ili pri točci vrenja otapala), prikladno u rasponu od 20-90 *C.
An embodiment of the present invention relates to a method for encoding at least one image split into partitions, such a method implementing the steps of: 
Računalno čitljiv nosač za bilježenje uključujući tok podataka koji predstavlja najmanje jednu sliku rastavljenu u particije, gdje je navedena slika kodirana ranije, gdje tok podataka sadrži:
The compound of claim 9 wherein R1 is H, F, methyl, or trifluoromethyl. 
Spoj u skladu s patentnim zahtjevom 9, naznačen time, da je R' H, FE, metil ili trifluorometil.
9% (worsened) 15% (2 grade improvement) 
9% (pogoršanje) 15% (poboljšanje 2. stupnja)
The compound or salt of any one of items 34-36, wherein the compound corresponds in structure to Formula (I-b): 
Spoj ili sol prema zahtjevu 14, naznačen time, da spoj ima strukturu koja odgovara Formuli (I-b): 25
The rate of application of the Sulfonylureas is usually 0.1 to 200 g/ha, as a rule 1 to 100 g/ha, preferably 2 to 100 g/ha, of active substance (a.s.). 
Stopa primjene imazamoksa je obično 0.1 do 200 g/ha, kao pravilo, 1 do 100 g/ha, poželjno 2 do 100 g/ha aktivne supstance.
A beverage preparation machine according to claim 1, wherein when the tank is located away from the switch, the switch actuates a display system in the machine that warns the user about the empty state of the tank. 
Stroj za pripravu napitaka (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što kada je spremnik (2) odmaknut od prekidača, navedeni prekidač uključuje prikazivački sustav u stroju koji upozorava korisnika o praznom stanju spremnika.
Public sanitary device as claimed in claim 1, wherein the housing comprises two or more walk-in positions, wherein at least one of the walk-in positions (20) is provided with the door and at least one of the walk-in positions (30) is not provided with the door. 
Javni sanitarni uređaj prema zahtjevu 1, pri čemu kućište ima dva ili više položaja u ravnini poda, pri čemu je najmanje jedan od položaja (20) u ravnini poda opremljen vratima 1 najmanje jedan od položaja (30) u ravnini poda nije opremljen vratima.
Formulations can include a divalent or trivalent cation. The divalent or trivalent cation can include, for example, magnesium, calcium, zinc, copper, aluminum, and iron. 
Aerosol za uporabu sukladno patentnom zahtjevu 1 ili patentnog zahtjeva 2, pri čemu se dvovalentni ili trovalentni kation odabire iz magnezija, kalcija, cinka, bakra, aluminija i željeza.
by the use of a reducing agent like borane, alane or lithium aluminium hydride. 
korištenjem reducirajućeg agensa kao što je to boran, alan ili litijev aluminijski hidrid.
about 300 millibars to about 700 millibars; and 
(i) od oko 300 railibara pa do 700 milibara; te
% A fifth example concerns a recipe for "quatre quarts cake" in which the following ingredients are used: 
U petom primjeru iznosi se recept za Â«quatre quarts kolač» za koji su potrebni sljedeći sastojci:
The method of claim 3, wherein the sample is collected at least one month after initiation of said neoadjuvant endocrine therapy. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što se uzorak uzima najmanje mjesec dana nakon početka navedene neoadjuvantne endokrine terapije.
and R5 together form a bivalent radical selected from methylenedioxy or ethylenedioxy; 
RiR> zajedno tvore bivalentni radikal odabran od metilendioksi ili etilendioksi;
The concentrated solution at 20-25° C. was treated with 1,1′-carbonyldiimidazole (21.46 g, 0.132 mol) and stirred at 20-25° C. for 1 hr then treated with water (290 mL) and stirred rapidly at 20-25° C. for 24 hr. 
Koncentriranu otopinu na 20-25 "C obradi se 1,1'-karbonildiimidazolom (21,46 g, 0,1 32 mol), miješa na 1 sat 20-25 "C, obradi vodom (290 ml), te brzo miješa 24 sata na 20-25 *C. Smjesu se ostavi da se
compacting the mixture obtained in step (a) in a roller compactor to produce granules; and 
(b) sabijanje smjese dobivene u koraku (a) u kompaktoru s valjcima kako bi se dobile granule; i
A process as claimed in claim 1, wherein the catalyst used for cyclization is a palladium (0) or (II) catalyst complex system. 
Postupak prema patentnom zahtjevu 1, naznačen time što je katalizator koji je korišten za ciklizaciju sustava kompleksa katalizatora paladija (0) ili (ID.
providing a solution comprising a Lewis acid and tetrahydrofuran; and adding the Lewis acid solution to the solution of the boron "ate" complex of formula (II) from step (a); 
(i) osiguranje otopine koja sadrži Lewis-ovu kiselinu i tetrahidrofuran; i (ii) dodavanja otopine Lewis-ove kiseline u otopinu kompleksa borata formule (17) iz koraka (a); pri čemu je otopljivost vode u eterskom otapalu koje ima nisku mješavost sa vodom manja od 5% tež./tež.; ili
The clinker as claimed in claim 1, wherein x varies from 2.1 to 2.9 and/or y varies from 0.05 to 0.5. 
3. <Klinker prema patentnom zahtjevu 1 ili 2, naznačen time da x varira od 2.1 do 2.9 i/ili y varira od 0.05 do 0.5.
Preferably, the underlined N refers to a nucleotide have a modified phosphodiester backbone. 
AJ te što se podcrtani nukleotid odnosi na nukleotid s fosforotioatnom okosnicom.
A compound according to claim 2, wherein the condition is lupus erythematosis. Use of a compound according to claim 1 to manufacture a medicament for use in the treatment of conditions or disorders mediated by S1 P1 receptors, wherein the condition or disorder is multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes. 
Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan i dijabetes neovisan o inzulinu.
Coupling device according to claim 1, wherein each hinge is configured to permit a corresponding latch to pivot within a plane including said longitudinal axis, X 1, and about a hinge axis normal to the longitudinal axis, X 1 . 
Uređaj za spajanje u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da svaki zglob (36) omogućuje odgovarajućem zasunu zakretanje unutar ravnine koja uključuje navedenu uzdužnu os, XI i oko osovine zgloba koji je okomit na uzdužnu os XI.
The antibody or antigen-binding fragment thereof for use of claim 24 or 25, wherein the antibody or antigen-binding fragment thereof is co-administered with a second therapeutic agent. 
Antitijelo ili njegov fragment vezan za antigen za uporabu prema zahtjevu 16 ili 17, naznačeno time što se antitijelo ili njegov fragment vezan za antigen primjenjuje istodobno s drugim terapijskim sredstvom.
The method of clause 43, wherein the irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPTV); and exercise-induced variants thereof. 
Spoj prema patentnom zahtjevu 12, naznačen time što su poremećaji i bolesti nepravilnog srčanog rada i poremećaji i bolesti nepravilnog srčanog rada indcirani pojačanom fizičkom aktivnošću izabrani iz grupe koju čine atrijalna 1 ventrikularna aritmija; atrijalna i ventrikularna fibrilacija; atrijalna i ventrikularna tahiaritmija; atrijalna 1 ventrikularna tahikardija; kateholaminergična polimorfna ventrikularna tahikardija (CPVT); i njihove varijante izazvane pojačanom fizičkom aktivnošću.
The microaggregated form preferentially distributed to lung, liver and kidney, whereas the monomeric product distributed almost 100% to the kidney. 
Mikroagregatni oblik pogodno se distribuirao u pluća, jetru i bubreg, dok se naprotiv monomerni proizvod distribuirao gotovo 100% u bubreg.
A compound of any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a composition of any of claims 8 to 10, for use in a method for treating nonalcoholic fatty liver disease (NAFLD) or hepatic insulin resistance in animals. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time što su namijenjeni upotrebi u liječenju nealkoholne bolesti masne jetre (NAFLD) ili jetrene otpornosti na inzulin.
The panel according to claim 1, wherein a part of a side of the upward tongue facing toward the upward flank forms an upward aligning edge for the purpose of coupling the third edge to a fourth edge of the second panel, wherein the first locking element is positioned at a lower level than the upward aligning edge. A panel, in particular a floor panel, interconnectable with similar panels for forming a covering, comprising: 
Ploča (1, 42, 43, 46, 53, 57) u skladu s jednim od prethodnih patentnih zahtjeva, pri čemu je prvi element zaključavanja (23, 64) postavljen na nižoj razini od gornjeg naliježućeg ruba (19b, 61b) na gore usmjerenog jezika Pokrov, posebno podni pokrov, koji se sastoji od međusobno povezanih ploča (1, 42, 43, 46, 53, 57) u skladu s bilo kojim od prethodnih patentnih zahtjeva.